WASHINGTON, Nov. 29, 2022 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced that Chief Executive Officer Seth Blackley, Chief Financial Officer John Johnson and Vice President, Investor Relations Seth Frank will participate in upcoming investor conferences.
A live audio-only webcast and replay for these events will be available on the Investor Relations section of Evolent's website at http://ir.evolenthealth.com/, unless otherwise noted below.
Evolent Health delivers proven clinical and administrative solutions that improve whole-person health while making health care simpler and more affordable. Our solutions encompass total cost of care management, specialty care management and administrative simplification. Evolent serves a national base of leading payers and providers, is the first company to receive the National Committee for Quality Assurance's Population Health Program Accreditation and is consistently recognized as a top place to work in health care nationally. Learn more about how Evolent is changing the way health care is delivered by visiting evolenthealth.com.
Contacts:
Seth R. Frank
Vice President, Investor Relations
Evolent Health, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
571-895-3919 (W)
Last Trade: | US$9.23 |
Daily Change: | -0.06 -0.65 |
Daily Volume: | 2,082,375 |
Market Cap: | US$1.060B |
February 20, 2025 February 04, 2025 November 07, 2024 November 07, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load